A novel outlook in the delivery of artemisinin: production and efficacy in experimental visceral leishmaniasis

References

• Vakili B, Nezafat N, Zare B, et al. A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice. Med Microbiol Immunol. 2020;209(1):69–79. DOI:10.1007/s00430-019-00640-7
   PubMed Web of Science ®Google Scholar
• Shirian S, Oryan A, GR H, et al. Three Leishmania/L. species–L. infantum, L. major, L. tropica–as causative agents of mucosal leishmaniasis in Iran. Pathog Glob Health. 2013;107(5):267–272.
   PubMed Web of Science ®Google Scholar
• Oryan A, Akbari M. Worldwide risk factors in leishmaniasis. Asian Pac J Trop Med. 2016;9(10):925–932.
   PubMed Web of Science ®Google Scholar
• Akbari M, Oryan A, Hatam G. Application of nanotechnology in treatment of leishmaniasis: a review. Acta tropica. 2017;172:86–90.
   PubMed Web of Science ®Google Scholar
• Akbari M, Oryan A, Hatam G. Immunotherapy in treatment of leishmaniasis. Immunol Lett. 2021;233:80–86.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chatterjee M. Visceral leishmaniasis-current therapeutic modalities. Indian J Med Res. 2006;123:345.
   PubMed Web of Science ®Google Scholar
• Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents. 2000;13(4):243–248.
   PubMed Web of Science ®Google Scholar
• Monge-Maillo B, López-Vélez R. Therapeutic options for visceral leishmaniasis. Drugs. 2013;73(17):1863–1888.
   PubMed Web of Science ®Google Scholar
• Natera S, Machuca C, Padrón-Nieves M, et al. Leishmania spp.: proficiency of drug-resistant parasites. Int J Antimicrob Agents. 2007;29(6):637–642.
   PubMed Web of Science ®Google Scholar
• Sen R, Bandyopadhyay S, Dutta A, et al. Artemisinin triggers induction of cell-cycle arrest and apoptosis in Leishmania donovani promastigotes. J Med Microbiol. 2007;56(9):1213–1218. DOI:10.1099/jmm.0.47364-0
   PubMed Web of Science ®Google Scholar
• Sen R, Ganguly S, Saha P, et al. Efficacy of artemisinin in experimental visceral leishmaniasis. Int J Antimicrob Agents. 2010;36(1):43–49.
   PubMed Web of Science ®Google Scholar
• McGready R, Van Vugt M, Phaipun L, et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg. 1999;60(4):547–555. DOI:10.4269/ajtmh.1999.60.547
   PubMed Web of Science ®Google Scholar
• McGready R, Cho T, Cho JJ, et al. Artemisinin derivatives in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med. 1998;92(4):430–433. DOI:10.1016/S0035-9203(98)91081-1
   PubMed Web of Science ®Google Scholar
• Chen Y, Lin X, Park H, et al. Study of artemisinin nanocapsules as anticancer drug delivery systems. Nanomedicine. 2009;5(3):316–322.
   PubMed Web of Science ®Google Scholar
• Saleem K, Khursheed Z, Hano C, et al. Applications of nanomaterials in leishmaniasis: a focus on recent advances and challenges. Nanomaterials. 2019;9(12):1749.
   Web of Science ®Google Scholar
• Want MY, Islamuddin M, Chouhan G, et al. Therapeutic efficacy of artemisinin-loaded nanoparticles in experimental visceral leishmaniasis. Colloids Surf B Biointerfaces. 2015;130:215–221.
   PubMed Web of Science ®Google Scholar
• Tuon FF, Dantas LR, RM DS, et al. Liposomal drug delivery systems for the treatment of leishmaniasis. Parasitology Research. 2022;121:3073–3082.
   Google Scholar
• RM DS, Maranhão RC, Tavares ER, et al. Lipid nanoparticles for amphotericin delivery in the treatment of American tegumentary leishmaniasis. Drug Deliv Transl Res. 2020;10(2):403–412. DOI:10.1007/s13346-019-00677-4
   PubMed Web of Science ®Google Scholar
• Bruni N, Stella B, Giraudo L, et al. Nanostructured delivery systems with improved leishmanicidal activity: a critical review. Int J Nanomed. 2017;12:5289.
   PubMed Web of Science ®Google Scholar
• Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Delivery. 2012;9(5):497–508.
   PubMed Web of Science ®Google Scholar
• Bobo D, Robinson KJ, Islam J, et al. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373–2387.
   PubMed Web of Science ®Google Scholar
• Stauber LA. Host resistance to the Khartoum strain of Leishmania donovani. New Brunswick, New Jersey: Rice Institute Pamphlet-Rice University Studies; 1958;45(1).
   Google Scholar
• Keiser J, Shu-Hua X, Jian X, et al. Effect of artesunate and artemether against Clonorchis sinensis and Opisthorchis viverrini in rodent models. Int J Antimicrob Agents. 2006;28(4):370–373. DOI:10.1016/j.ijantimicag.2006.08.004
   PubMed Web of Science ®Google Scholar
• Danso-Appiah A, Garner P, Olliaro P, et al. Treatment of urinary schistosomiasis: methodological issues and research needs identified through a Cochrane systematic review. Parasitology. 2009;136(13):1837–1849.
   PubMed Web of Science ®Google Scholar
• Ghaffarifar F, Heydari FE, Dalimi A, et al. Evaluation of apoptotic and antileishmanial activities of Artemisinin on promastigotes and BALB/C mice infected with Leishmania major. Iran j parasitol. 2015;10:258.
   PubMed Web of Science ®Google Scholar
• Angus B. Novel anti-malarial combinations and their toxicity. Expert Rev Clin Pharmacol. 2014;7(3):299–316.
   PubMed Web of Science ®Google Scholar
• Jebali A, Kazemi B. Nano-based antileishmanial agents: a toxicological study on nanoparticles for future treatment of cutaneous leishmaniasis. Toxicol in vitro. 2013;27(6):1896–1904.
   PubMed Web of Science ®Google Scholar
• Mol M, Kosey D, Singh S. Nano-synthetic devices in leishmaniasis: a bioinformatics approach. Front Immunol. 2015;6:323.
   PubMed Web of Science ®Google Scholar
• Cardona-Arias JA, Vélez ID, Lopez-Carvajal L. Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials. PLoS ONE. 2015;10(5):e0122569.
   PubMed Web of Science ®Google Scholar
• Want MY, Islamuddin M, Chouhan G, et al. A new approach for the delivery of artemisinin: formulation, characterization, and ex-vivo antileishmanial studies. J Colloid Interface Sci. 2014;432:258–269.
   PubMed Web of Science ®Google Scholar
• Want MY, Islammudin M, Chouhan G, et al. Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis. Int J Nanomed. 2017;12:2189.
   PubMed Web of Science ®Google Scholar
• Roy P, Das S, Bera T, et al. Andrographolide nanoparticles in leishmaniasis: characterization and in vitro evaluations. Int J Nanomed. 2010;5:1113.
   PubMed Web of Science ®Google Scholar
• Shastri DH. Effective delivery routes and strategies for solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). Curr Pharm Des. 2017;23(43):6592–6601.
   Web of Science ®Google Scholar
• Monteiro LM, Löbenberg R, Cotrim PC, et al. Buparvaquone nanostructured lipid carrier: development of an affordable delivery system for the treatment of leishmaniases. Bio Med Res Int. 2017;2017:1–11.
   Google Scholar
• Gupta GK, Kansal S, Misra P, et al. Uptake of biodegradable gel-assisted LBL nanomatrix by Leishmania donovani-infected macrophages. AAPS Pharm Sci Tech. 2009;10(4):1343.
   PubMed Web of Science ®Google Scholar
• Van de Ven H, Vermeersch M, Vandenbroucke R, et al. Intracellular drug delivery in Leishmania-infected macrophages: evaluation of saponin-loaded PLGA nanoparticles. J Drug Targeting. 2012;20(2):142–154. DOI:10.3109/1061186X.2011.595491
   PubMed Web of Science ®Google Scholar
• Heidari‐kharaji M, Taheri T, Doroud D, et al. Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model. Parasite Immunol. 2016;38(10):599–608.
   PubMed Web of Science ®Google Scholar
• Heidari-Kharaji M, Taheri T, Doroud D, et al. Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB/c mice model. Appl Microbiol Biotechnol. 2016;100(16):7051–7060.
   PubMed Web of Science ®Google Scholar
• Jain V, Gupta A, Pawar VK, et al. Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles. Appl Biochem Biotechnol. 2014;174(4):1309–1330. DOI:10.1007/s12010-014-1084-y
   PubMed Web of Science ®Google Scholar
• JJ DGB, Pazin WM, Ito AS, et al. Miltefosine-loaded lipid nanoparticles: improving miltefosine stability and reducing its hemolytic potential toward erythtocytes and its cytotoxic effect on macrophages. Biophys Chem. 2016;217:20–31.
   PubMed Web of Science ®Google Scholar
• Dietze R, Fagundes S, Brito E, et al. Treatment of kala-azar in Brazil with AmphocilsR (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med. 1995;89(3):309–311. DOI:10.1016/0035-9203(95)90557-X
   PubMed Web of Science ®Google Scholar